Program
Gabapentin
Also written as “gabapentin”, “gabapentin 600 mg” and “Gabapentin Extended Release tablets”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Hot Flashes · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 8 companies.
Drug pageGabapentin: every studyMany companies study it; this page follows only the 44 they lead. All 334 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 201 open or running | phase 4since Sep 28, 2007 | Sep 8, 2005 | Jan 31, 2027phase 4 · NCT07813026 |
| Depomed | 80 open or running | phase 4since Jun 5, 2017 | Jun 8, 2006 | none ahead |
| Teva Pharmaceutical Industriesits history only | 60 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 40 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since Sep 29, 2011 | Sep 29, 2011 | none ahead |
| Pharmaceutical Research Management srlits history only | 20 open or running | phase 3since Mar 18, 2016 | Mar 18, 2016 | none ahead |
| Nang Kuang Pharmaceuticalits history only | 10 open or running | phase 4since Feb 24, 2014 | Feb 24, 2014 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since May 5, 2010 | May 5, 2010 | none ahead |
Also a collaborator on its studies: Chiltern International and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Depomed only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 8, 2006First study: phase 3 study in Neuralgia, PostherpeticFirst studyNCT00335933 · 378 enrolled · United States
- Aug 2, 2007Phase 2 study in Hot FlashesNCT00511953 · 108 enrolled · United States
- Feb 21, 2008Phase 3 study in Neuralgia, PostherpeticNCT00636636 · 452 enrolled · United States, Argentina, Russian Federation
- Jul 8, 2008Phase 2 study in PainNCT00712439 · 147 enrolled
- Sep 17, 2008Phase 3 study in Hot FlashesNCT00755417 · 541 enrolled · United States
- Oct 21, 2008Phase 3 study in Hot FlashesNCT00777023 · 565 enrolled · United States
- Mar 2, 2010Phase 3 study in Hot FlashesNCT01080300 · 600 enrolled · United States
- Jun 5, 2017Phase 4 study in HealthyNCT03179345 · 32 enrolled
TargetBeta
“Voltage-gated calcium channel modulator”ChEMBL 37, by rule
Other programs on the same 26 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pregabalinrule | Viatris | phase 4 | 149 |
Studies
All 8 Depomed leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03179345Healthy | 4 | Completed | Nov 20, 2015 | 32 |
| NCT01080300Hot Flashes · United States | 3 | Completed | Sep 2011 | 600 |
| NCT00777023Hot Flashes · United States | 3 | Completed | Jul 2009 | 565 |
| NCT00755417Hot Flashes · United States | 3 | Completed | Aug 2009 | 541 |
| NCT00712439Pain | 2 | Completed | Nov 2006 | 147 |
| NCT00636636Neuralgia, Postherpetic · United States, Argentina, Russian Federation | 3 | Completed | Aug 2009 | 452 |
| NCT00511953Hot Flashes · United States | 2 | Completed | Dec 2007 | 108 |
| NCT00335933Neuralgia, Postherpetic · United States | 3 | Completed | 378 |
How it is read
Names in the registry
- “Gabapentin”, 27 entries
- “gabapentin”, 5 entries
- “gabapentin 600 mg”, 3 entries
- “Gabapentin Extended Release tablets”, 3 entries
- “Gabapentin 800 mg tablets, single dose (1 tablet)”, 3 entries
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 10 studies
- Hot Flashes, 4 studies
- Diabetic Neuropathies, 3 studies
- Epilepsies, Partial, 3 studies
- Neuralgia, Postherpetic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.